Kozak & Associates’s Novo Nordisk NVO Stock Holding History

Kozak & Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.9K	Hold	593	–	–	0.01%	178
2026 Q1	$22.5K	Hold	593	–	–	﹤0.01%	191
2025 Q4	$34.9K	Hold	593	–	–	0.01%	163
2025 Q3	$28.7K	Buy	593 +113	+24%	+$6.61K	0.01%	178
2025 Q2	$33.5K	Hold	480	–	–	0.01%	170
2025 Q1	$31.7K	Hold	480	–	–	0.01%	147
2024 Q4	$42.1K	Hold	480	–	–	0.01%	139
2024 Q3	$56.7K	Hold	480	–	–	0.01%	126
2024 Q2	$66.7K	Hold	480	–	–	0.02%	113
2024 Q1	$63.9K	Sell	480 -406	-46%	-$48.3K	0.02%	118
2023 Q4	$94.2K	Hold	886	–	–	0.03%	106
2023 Q3	$81.6K	Hold	886	–	–	0.03%	111
2023 Q2	$70.6K	Hold	886	–	–	0.03%	119
2023 Q1	$70.5K	Hold	886	–	–	0.03%	122
2022 Q4	$60K	Hold	886	–	–	0.03%	134
2022 Q3	$46K	Hold	886	–	–	0.03%	147
2022 Q2	$49K	Hold	886	–	–	0.03%	147
2022 Q1	$46K	Hold	886	–	–	0.03%	163
2021 Q4	$46K	Hold	886	–	–	0.03%	163
2021 Q3	$50K	Buy	+886	New	+$42.8K	0.03%	156

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Kozak & Associates's NVO Position: Q2 2026 in Review

Kozak & Associates held its Novo Nordisk (NVO) position steady in Q2 2026 at 593 shares worth $28.9K. The position accounts for 0.01% of the portfolio, ranked #178.

Kozak & Associates first reported a position in NVO in Q3 2021 and has held it in 20 quarters since. The position peaked at $94.2K in Q4 2023. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Kozak & Associates held 593 shares of Novo Nordisk worth $28.9K as of Q2 2026.
Kozak & Associates left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.01% of Kozak & Associates's portfolio in Q2 2026, its #178 holding.
Kozak & Associates first reported a position in Novo Nordisk in Q3 2021 and has held it in 20 quarters since.
Kozak & Associates's Novo Nordisk position peaked at $94.2K in Q4 2023.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.